. Author manuscript; available in PMC: 2020 Sep 1.

Published in final edited form as: Cancer. 2019 May 8;125(17):3013–3024. doi: 10.1002/cncr.32162

TABLE 2.

Outcomes by Trial

Trial	E1684	E1690	E1694	E2696	All Trials
Median follow-up, y	18.2	12.3	16.3	16.5	14.8
Observation, no.	140	212			352
Recurrent disease/died^a	106	133			239
Died	100	123			223
High-dose IFN, no.	146	215	438		799
Recurrent disease/died^a	97	125	222		444
Died	99	121	234		454
GMK, no.			439	35	474
Recurrent disease/died^a			249	23	272
Died			257	21	278
Other, no.		215		72	287
Recurrent disease/died^a		131		41	172
Died		116		42	158
Total	286	642	877	107	1912

Abbreviations: GMK, ganglioside GM2/keyhole limpet hemocyanin vaccine; IFN, interferon.

Recurrent disease/died indicates the number of patients who developed disease recurrence or died in the absence of disease recurrence.